SGS already posses a 60,000 Sq. Ft. manufacturing facility in the tax free zone of Roorkee.
SGS will invest close to US $ 1 million or INR 5 crore, the planned investment will be raised on Exhilway Private Capital Market (EPCM) by participating in the proposed private equity fund.
EPCM has marked a intrinsic valuation of US $10.65 million or INR 59 crore for SGS Pharma. As per the valuations, SGS will undergo equity dilution of close to 9%.
“We are committed to grow globally by launching our highly affordable pharmaceutical products. We are committed to achieve excellence in our area of expertise and we believe that with our efficient team in place we are bound to grow leaps and folds,” said Nnimish Gupta, Director of SGS Pharmaceutical.
SGS was incorporated in the year 2001 and is since then serving many multinationals like Morepen Laboratories, Elder Pharma, Gufic and Natco.
SGS will be the first pharmaceutical company from India to raise money on secondary markets. Raising money on secondary markets like EPCM is far easier than the banks, who charge higher interest rates and provide inadequate capital.
“The pharmaceutical industry in India is the third largest in the world in the terms of volume and 14th largest in the terms of value. The small and mid sized pharmaceutical companies in the tax free zones of Himachal Pradesh, Uttar Pradesh and Jharkhand is already finding it hard to upgrade their facilities, thus, resulting in closure of many units. SGS has thus made a right move to fund its expansion plans via private equity route,” says Anthony Short, former employee of Cipla.
EPCM helps businesses to raise funds from its registered investors on the basis of their intrinsic business valuation and helps them prepare for the initial public offering (IPO). Over 50,000 small and large investors are already part of EPCM.